A prospective observational study to explore the correlation of peripheral arterial pulse/resistance index, organ function, and inflammation in patients with septic shock

Clinical efficacy of ulinastatin in the treatment of unliquefied pyogenic liver abscess complicated by septic shock: A randomized controlled trial

INTRODUCTION

This study determined the therapeutic effect of ulinastatin (UTI) on unliquefied pyogenic liver abscesses complicated by septic shock (UPLA-SS).

METHODS

This was a randomized controlled trial involving patients with UPLA-SS who underwent treatment at our hospital between March 2018 and March 2022. The patients were randomly divided into control (n = 51) and study groups (n = 48). Both groups received routine treatment, but the study group received UTI (200,000 units q8h for >3 days). Differences in liver function, inflammatory indices, and effectiveness between the two groups were recorded.

RESULTS

Following treatment, the white blood cell count, and lactate, C-reactive protein, procalcitonin, tumor necrosis factor-α, and interleukin-6 levels were significantly decreased in all patients compared to the admission values (p < .05). The study group had a faster decline with respect to the above indices compared to the control group (p < .05). The study group length of intensive care unit stay, fever duration, and vasoactive drug maintenance time were all significantly shorter than the control group (p < .05). The total bilirubin, alanine aminotransferase, and aspartate aminotransferase levels were significantly lower in the study and control groups after treatment compared to before treatment (p < .05); however, the study group had a faster recovery of liver function than the control group (p < .05). The overall mortality rate was 14.14% (14/99); 10.41% of the study group patients died and 17.65% of the control group patients died, but there was no statistically significant difference between the two groups (p > .05).

CONCLUSION

UTI combined with conventional treatment significantly controlled the infection symptoms, improved organ function, and shortened the treatment time in patients with UPLA-SS.

Efficacy of Etimicin Sulfate Combined with Cefotaxime Sodium in the Treatment of Patients with Septic Shock and Effect on Serum Inflammatory Factor Levels and Immune Function

OBJECTIVE

To explore the effect of etimicin sulfate combined with cefotaxime sodium and cefotaxime sodium alone in the treatment of patients with septic shock and the effect on serum inflammatory factor levels and immune function.

METHODS

Total of 95 patients with septic shock who were treated in our hospital from March 2018 to July 2020 were collected as the subjects of this study. Among them, 44 patients who received cefotaxime sodium treatment and were included in the control group, and 51 patients who received etimicin sulfate combined with cefotaxime sodium treatment were included in the research group. The levels of serum IL-6 (interleukin-6), PCT (procalcitonin), TNF-α (tumor necrosis factor-α), CD3+ (cluster of differentiation 3+), CD4+, CD4+/CD8+, FIB (fibrinogen), and PT (prothrombin time), APTT (activated partial thromboplastin time) time before and after treatment, and the treatment effects, mechanical ventilation time, hospitalization time, and incidence of adverse reactions between the two groups were compared.

RESULTS

The total effective rate of treatment in the research group (90.20%) was higher than the control group (72.73%) (p < 0.05). After treatment, the serum levels of IL-6, PCT, and TNF-α, FIB, CD3+, CD4+, CD4+/CD8+, and PT and APTT time in the two groups of patients have improved significantly (p < 0.05). Compared with the control group, the research group's IL-6, PCT, TNF-α levels, PT, and APTT decreased more, and FIB, CD3+, CD4+, and CD4+/CD8+ levels increased more (p < 0.05). The mechanical ventilation time and hospital stay of the research group were significantly shorter than the control group (p < 0.05). There was no significant difference between the total incidence of adverse reactions in the research group (15.69%) and the control group (9.09%) (p > 0.05).

CONCLUSION

Compared with cefotaxime sodium alone, the treatment of etimicin sulfate combined with cefotaxime sodium is more effective in improving the coagulation function and cellular immune function of patients with septic shock, reducing the level of serum inflammatory factors, and having higher clinical treatment effective.